ABBVIE INC logo

ABBVIE INC (ABBVD)

Market Closed
14 Jul, 16:09
BCBA BCBA
$
19. 00
-0.4
-2.06%
$
- Market Cap
42.2 P/E Ratio
6.2% Div Yield
8 Volume
10.28 Eps
$ 19.4
Previous Close
Day Range
19 19.3
Year Range
16.2 21.8
Want to track ABBVD and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 7 days

Summary

ABBVD closed Monday lower at $19, a decrease of 2.06% from Friday's close, completing a monthly increase of 1.88% or $0.35. Over the past 12 months, ABBVD stock gained 4.97%.
ABBVD pays dividends to its shareholders, with the most recent payment made on May 15, 2025. The next estimated payment will be in In 4 weeks on Aug 15, 2025 for a total of $1.64.
The last earnings report, released on Apr 24, 2025, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -0.01%, based on the last three reports. The next scheduled earnings report is due on Jul 23, 2025.
The stock of the company had never split.
The company's stock is traded on 16 different exchanges and in various currencies, with the primary listing on NYSE (USD).

ABBVD Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
AbbVie (ABBV) Surpasses Market Returns: Some Facts Worth Knowing

AbbVie (ABBV) Surpasses Market Returns: Some Facts Worth Knowing

The latest trading day saw AbbVie (ABBV) settling at $190.58, representing a +2.25% change from its previous close.

Zacks | 1 hour ago
How Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?

How Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?

ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.

Zacks | 10 hours ago
Here's How to Play AbbVie Stock as it Reaches Golden Cross

Here's How to Play AbbVie Stock as it Reaches Golden Cross

ABBV hits a bullish golden cross as Skyrizi and Rinvoq drive growth, offsetting Humira losses and aesthetic headwinds.

Zacks | 1 day ago

ABBVIE INC Dividends

AbbVie Inc. logo
ABBV 3 months ago
Paid
Quarterly
$1.64 Per Share
AbbVie Inc. logo
ABBV 6 months ago
Paid
Quarterly
$1.64 Per Share
AbbVie Inc. logo
ABBV 9 months ago
Paid
Quarterly
$1.55 Per Share
AbbVie Inc. logo
ABBV 15 Jul 2024
Paid
Quarterly
$1.55 Per Share
AbbVie Inc. logo
ABBV 12 Apr 2024
Paid
Quarterly
$1.55 Per Share

ABBVIE INC Earnings

23 Jul 2025 (In 1 week) Date
3.22
Cons. EPS
-
EPS
24 Apr 2025 Date
-
Cons. EPS
-
EPS
31 Jan 2025 Date
2.26
Cons. EPS
2.16
EPS
30 Oct 2024 Date
2.92
Cons. EPS
3
EPS
25 Oct 2024 Date
2.95
Cons. EPS
-
EPS
AbbVie Inc. logo
ABBV 3 months ago
Paid
Quarterly
$1.64 Per Share
AbbVie Inc. logo
ABBV 6 months ago
Paid
Quarterly
$1.64 Per Share
AbbVie Inc. logo
ABBV 9 months ago
Paid
Quarterly
$1.55 Per Share
AbbVie Inc. logo
ABBV 15 Jul 2024
Paid
Quarterly
$1.55 Per Share
AbbVie Inc. logo
ABBV 12 Apr 2024
Paid
Quarterly
$1.55 Per Share
23 Jul 2025 (In 1 week) Date
3.22
Cons. EPS
-
EPS
24 Apr 2025 Date
-
Cons. EPS
-
EPS
31 Jan 2025 Date
2.26
Cons. EPS
2.16
EPS
30 Oct 2024 Date
2.92
Cons. EPS
3
EPS
25 Oct 2024 Date
2.95
Cons. EPS
-
EPS

ABBVIE INC (ABBVD) FAQ

What is the stock price today?

The current price is $19.00.

On which exchange is it traded?

ABBVIE INC is listed on NYSE.

What is its stock symbol?

The ticker symbol is ABBVD.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 6.2%.

What is its market cap?

As of today, no market cap data is available.

What is the earnings per share?

The EPS is 3.22.

When is the next earnings date?

The next earnings report will release on Jul 23, 2025.

Has ABBVIE INC ever had a stock split?

No, there has never been a stock split.

ABBVIE INC Profile

Drug Manufacturers - General Industry
Healthcare Sector
Robert A. Michael CPA CEO
BCBA Exchange
US00287Y1091 ISIN
US Country
55,000 Employees
15 Apr 2025 Last Dividend
- Last Split
2 Jan 2013 IPO Date

Overview

AbbVie Inc. is a global pharmaceutical company engaged in the discovery, development, manufacturing, and sales of a wide range of pharmaceutical products. Incorporated in 2012 and headquartered in North Chicago, Illinois, AbbVie focuses on addressing some of the world's most complex and critical health issues through its innovative medicines and therapies. In addition to its stand-alone operations, the company collaborates with several other leading institutions, including Calico Life Sciences LLC, REGENXBIO Inc., Janssen Biotech, Inc., Genentech, Inc., and Tentarix Biotherapeutics, LP. These collaborations aim to enhance AbbVie's research and development capabilities, particularly in the areas of oncology and immunology.

Products and Services

  • Humira: A therapeutic injection for various autoimmune diseases, including intestinal Behçet's disease and pyoderma gangrenosum.
  • Skyrizi: Prescribed for patients with moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease, focusing on improving skin health.
  • Rinvoq: Targets multiple conditions such as rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, and several gastrointestinal diseases.
  • Imbruvica: An oral medication for adults with various blood cancers, marking significant advancements in oncology.
  • Epkinly and Elahere: Treatments tailored for different forms of lymphoma and cancer, showcasing AbbVie's innovations in targeted therapies.
  • Venclexta/Venclyxto: Offers hope for patients battling blood cancers, through a regimen that interferes with cancer cell survival.
  • Aesthetic Products: A range of facial injectables, plastics and regenerative medicine, body contouring, and skincare offerings that cater to aesthetic needs.
  • Botox Therapeutic: Beyond cosmetic applications, this product is utilized for various therapeutic purposes, enhancing patient care.
  • Vraylar: A medication designed to address depressive disorder, contributing to mental health treatment options.
  • Duopa and Duodopa: These formulations provide relief for patients with advanced Parkinson's disease, improving quality of life.
  • Ubrelvy and Qulipta: Target the acute treatment of migraine in adults, including both episodic and chronic forms.
  • Ozurdex: An ocular implant designed to treat eye diseases, emphasizing AbbVie's contribution to ophthalmology.
  • Lumigan/Ganfort and Alphagan/Combigan: Aimed at reducing intraocular pressure in conditions like open-angle glaucoma or ocular hypertension.
  • Restasis: Helps increase tear production, addressing the needs of patients with dry eye disease.
  • Mavyret/Maviret: Administered for the treatment of chronic hepatitis C virus (HCV) infection, representing a breakthrough in HCV treatment.
  • Creon: A pancreatic enzyme therapy essential for patients with pancreatic insufficiency, aiding digestion.
  • Lupron: Utilized for treating advanced prostate cancer, endometriosis, central precocious puberty, and uterine fibroids-related anemia.
  • Linzess/Constella: Offers relief for irritable bowel syndrome with constipation and chronic idiopathic constipation.
  • Synthroid: A synthetic thyroid hormone used to treat hypothyroidism, ensuring thyroid hormone levels are balanced.

Contact Information

Address: 1 North Waukegan Road
Phone: 847 932 7900